睑板腺挤压辅助治疗原发性干燥综合征相关干眼的临床价值OA

Objective To explore the effectiveness and safety of meibomian gland compression-assisted treatment for dry eye associated with primary Sjögren's syndrome(pSS).Methods A prospective randomized controlled study was conducted.From February 2021 to December 2024,33 patients with pSS who were diag-nosed with moderate to severe dry eye disease in this hospital were selected as the research subjects.They were randomly divided into the treatment group and the control group.Both groups received the same system-ic medication and eye drops treatment.Patients in the treatment group also received meibomian gland com-pression therapy.The standard dry eye symptom assessment(SPEED)questionnaire scores,ocular surface disease index(OSDI)questionnaire scores,tear secretion test,lipid layer thickness,tear meniscus height,tear film break-up time(TBUT),best corrected visual acuity(BCVA),and corneal staining index(OSS)scores of the two groups were observed before treatment and at 1 and 3 months after treatment.Results After treat-ment,the scores of the SPEED and OSDI questionnaires in both groups significantly decreased(P<0.05),but there was no statistically significant difference between the two groups(P>0.05),and there was also no sta-tistically significant difference in the trend of change between the two groups(P>0.05).The thickness of the lipid layer and TBUT in both groups significantly improved over time(P<0.05),and the lipid layer thickness and TBUT in the treatment group improved more significantly at 1 month after treatment(P<0.05).There was a statistically significant difference in the comparison of tear secretion volume between the two groups(P<0.05),and the tear secretion volume in the treatment group was significantly higher than that in the con-trol group after treatment,especially at 1 month.The change in tear meniscus height within both groups was statistically significant over time(P<0.05),and the tear meniscus height significantly increased,but there was no statistically significant difference or trend between the two groups(P>0.05).There was no statisti-cally significant difference in the change of BCVA between the two groups(P>0.05).There was a statistical-ly significant difference in the comparison of corneal OSS scores between the two groups(P<0.05),and the corneal OSS score in the treatment group was significantly lower than that in the control group after treat-ment,and the corneal OSS score in both groups decreased significantly over time(P<0.05).Conclusion Conven-tional treatment can effectively alleviate the dry eye symptoms and signs of patients with pSS.Combined with meibomian gland compression-assisted therapy,it can significantly increase the tear secretion volume and re-duce the corneal OSS score,with good efficacy and safety.